(IN BRIEF) The Phase III RAMPART trial has demonstrated that combining the immunotherapy drugs durvalumab and tremelimumab after surgery significantly improves disease-free survival in patients with early-stage renal cell carcinoma (RCC). Led by the Medical Research Council Clinical Trials Unit … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca UK Limited, cancer recurrence, clinical trial, Combination Therapy, disease-free survival, durvalumab, ESMO 2025, European Society for Medical Oncology, ICR, immunotherapy, kidney cancer, Medical Research Council Clinical Trials Unit, MRC CTU, oncology research, precision medicine, Professor Angela Meade, Professor James Larkin, RAMPART trial, RAMPART trial confirms combination immunotherapy reduces recurrence risk in kidney cancer after surgery, RCC, renal cell carcinoma, The Institute of Cancer Research and Royal Marsden report breakthrough results in renal cancer immunotherapy trial, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust, tremelimumab, UCL, University College London
(IN BRIEF) Long-term data from the international monarchE trial has confirmed that patients with HR+ and HER2- node-positive high-risk early breast cancer achieve better survival outcomes when treated with the targeted therapy abemaciclib in combination with standard hormone therapy. Presented … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abemaciclib, Annals of Oncology, clinical trial, early breast cancer, Eli Lilly and Company, ESMO 2025, European Society for Medical Oncology, HER2 negative, high-risk breast cancer, hormone therapy, HR-positive, ICR, Long-term monarchE study confirms abemaciclib improves survival for high-risk early breast cancer patients, Long-Term Survival, metastatic disease, monarchE trial, National Institute for Health and Care Research, New monarchE data shows first major advance in adjuvant breast cancer survival outcomes in two decades, NIHR, oncology research, Professor Stephen Johnston, targeted therapy, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust
(IN BRIEF) In recognition of World Statistics Day 2025, The Institute of Cancer Research (ICR), London, is spotlighting the essential role of statisticians in advancing cancer research through reliable, transparent, and responsible data analysis. The event, themed “Quality statistics and … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adaptive trial designs, artificial intelligence, biostatistics, cancer trials, clinical research, Clinical Trials and Statistics Unit, Covid-19 pandemic, CTSU, data transparency, Emily Alger, evidence-based decision making, ICR, ICR showcases how statistical science powers cancer research and clinical progress for World Statistics Day 2025, Machine Learning, oncology research, patient-reported outcomes, Professor Christina Yap, quality statistics, responsible research, statistical science, The Institute of Cancer Research celebrates the power of statistics in advancing cancer research ahead of World Statistics Day 2025, The Institute of Cancer Research London, University of Oxford, University of Warwick, World Statistics Day 2025
(IN BRIEF) A new global analysis by The Institute of Cancer Research (ICR), London, has found that cancer incidence is rising in both younger and older adults, disputing the idea that the global increase is limited to those under 50. … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Annals of Internal Medicine, bowel cancer, breast cancer, cancer incidence, Cancer Prevention, early-onset cancer, endometrial cancer, epidemiology, Global analysis from ICR challenges belief that cancer surge affects only younger adults, Global study, global trends, GLOBOCAN, IARC, ICR, International Agency for Research on Cancer, kidney cancer, leukaemia, Obesity, Older Adults, Professor Amy Berrington, Professor Kristian Helin, public health, screening, The Institute of Cancer Research London, The Institute of Cancer Research study finds cancer rates rising among both younger and older adults worldwide, thyroid cancer, World Health Organization, younger adults
(IN BRIEF) Researchers at The Institute of Cancer Research and Queen Mary University have created EIRAs, a computational assay that predicts how bowel cancer cells evolve resistance to chemotherapy. By monitoring cell populations and applying evolutionary models, the tool differentiates … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Science, Technology, United Kingdom
Tagged bowel cancer, breast cancer, Cancer Research UK, chemotherapy resistance, colorectal cancer, drug discovery, EIRAs, evolutionary biology, Evolutionary Informed Resistance Assays, Freddie Whiting, genetic mutation, Kristian Helin, Machine Learning, Nature Communications, non-genetic adaptation, ovarian cancer, patent, personalized therapy, Queen Mary University of London, Richard Nichols, The Institute of Cancer Research London, Trevor Graham, Wellcome Trust
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?